ANAPTYSBIO, INC Logo

ANAPTYSBIO, INC

Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.

ANAB | US

Overview

Corporate Details

ISIN(s):
US0327241065
LEI:
Country:
United States of America
Address:
10770 WATERIDGE CIRCLE, SUITE 210, 92121 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnaptysBio, Inc. is a clinical-stage biotechnology company that develops innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab, a pathogenic T cell depleter in Phase 2b trials for rheumatoid arthritis, and ANB033, a CD122 antagonist. AnaptysBio has announced plans to separate its biopharmaceutical operations from its royalty assets into two independent, publicly traded companies by year-end 2026 to align with different investor strategies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ANAPTYSBIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ANAPTYSBIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ANAPTYSBIO, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medicus Pharma Ltd. Logo
A clinical-stage holding company advancing novel drugs, biologics, and devices to market.
United States of America MDCX
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America MGTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.